Advertisement
Screener

VHCP Management, LLC Historic Quarter Change: USA Stocks, Reduced

VHCP Management, LLC historic quarter change: USA Stocks, Reduced

In share positions in stocks (listed in the US), over 13 quarters from 2013-06-30 to 2016-09-30, VHCP Management, LLC opened 7 positions, added to 3, reduced 13 and sold out of 5.

  • Q3 2016: Stock CHRS; Country of operation United States; Class COM; Shares before 611,010.
  • Q3 2016: Stock RGNX; Country of operation United States; Class COM; Shares before 52,500.
  • Q1 2016: Stock CTMX; Country of operation United States; Class COM; Shares before 75,000.
  • Q4 2015: Stock RGNX; Country of operation United States; Class COM; Shares before 1,083,454.

Each consecutive pair of Form 13F-HR filings compared (SEC CIK 1479355), 13 quarters: Q3 2016 (2016-06-30 to 2016-09-30, filed 2016-11-14); Q2 2016 (2016-03-31 to 2016-06-30, filed 2016-08-12); Q1 2016 (2015-12-31 to 2016-03-31, filed 2016-05-13); Q4 2015 (2015-09-30 to 2015-12-31, filed 2016-02-12); Q3 2015 (2015-06-30 to 2015-09-30, filed 2015-11-13); Q2 2015 (2015-03-31 to 2015-06-30, filed 2015-08-13); Q1 2015 (2014-12-31 to 2015-03-31, filed 2015-05-14); Q4 2014 (2014-09-30 to 2014-12-31, filed 2015-02-13); Q3 2014 (2014-06-30 to 2014-09-30, filed 2014-11-13); Q2 2014 (2014-03-31 to 2014-06-30, filed 2014-08-13); Q1 2014 (2013-12-31 to 2014-03-31, filed 2014-05-14); Q4 2013 (2013-09-30 to 2013-12-31, filed 2014-02-13); Q3 2013 (2013-06-30 to 2013-09-30, filed 2013-11-15). Rows for the same security, class and put/call are added together. Value change is the filed value at each quarter end, so it includes the price move. Only the filings held here are compared; the firm's 13F-HR filings go back to the quarter ended 2010-12-31.

QuarterStockCountry of operationClassShares beforeShares afterShare changeValue beforeValue afterValue changeFiled
Q3 2016CHRS
Coherus Biosciences Inc
United StatesCOM611,010305,505-305,505$10,320,000$8,181,000-$2,139,0002016-11-14
Q3 2016RGNX
REGENXBIO Inc
United StatesCOM52,50024,089-28,411$420,000$337,000-$83,0002016-11-14
Q1 2016CTMX
CytomX Therapeutics Inc
United StatesCOM75,00064,200-10,800$1,565,000$828,000-$737,0002016-05-13
Q4 2015RGNX
REGENXBIO Inc
United StatesCOM1,083,45452,500-1,030,954$20,178,000$872,000-$19,306,0002016-02-12
Q4 2015CHRS
Coherus Biosciences Inc
United StatesCOM870,269611,010-259,259$17,441,000$14,029,000-$3,412,0002016-02-12
Q2 2015BCRX
BioCryst Pharmaceuticals Inc
United StatesCOM1,744,356373,686-1,370,670$15,752,000$5,579,000-$10,173,0002015-08-13
Q1 2014IRWD
Ironwood Pharmaceuticals Inc
United StatesCOM1,800,000900,000-900,000$20,898,000$11,088,000-$9,810,0002014-05-14
Q1 2014BCRX
BioCryst Pharmaceuticals Inc
United StatesCOM1,754,3561,744,356-10,000$13,333,000$18,455,000+$5,122,0002014-05-14
Q1 2014NBIX
Neurocrine Biosciences Inc
United StatesCOM694,903303,503-391,400$6,490,000$4,886,000-$1,604,0002014-05-14
Q4 2013NBIX
Neurocrine Biosciences Inc
United StatesCOM1,271,303694,903-576,400$14,391,000$6,490,000-$7,901,0002014-02-13
Q4 2013BCRX
BioCryst Pharmaceuticals Inc
United StatesCOM2,180,6561,754,356-426,300$15,875,000$13,333,000-$2,542,0002014-02-13
Q3 2013NBIX
Neurocrine Biosciences Inc
United StatesCOM1,964,6731,271,303-693,370$26,287,000$14,391,000-$11,896,0002013-11-15
Q3 2013VNDA
Vanda Pharmaceuticals Inc
United StatesCOM787,459491,075-296,384$6,363,000$5,377,000-$986,0002013-11-15

Similar Firms

Firm NameCountry13F ValueHoldings
Not available yet